New Results on Rivaroxaban

Research data presented Sunday, November 13, 2011 at the American Heart Association Scientific Sessions indicated that adding low doses of Johnson & Johnson and Bayer’s Xarelto (rivaroxaban) to standard antiplatelet therapy significantly prevented the occurrence of secondary cardiovascular events in patients with acute coronary syndrome (ACS), compared with standard therapy alone. The companies plan to seek US and European approval of Xarelto for use in patients with ACS by the end of the year.